Researchers examined data on 5,617 women during their first
pregnancies, including 1,106 who said they had been diagnosed with
asthma. The women had babies between 2004 and 2011 in New Zealand,
Australia, Ireland and the UK.
Compared with non-asthmatics, women with current asthma who used
only short-acting “rescue” medications like albuterol were 15
percent less likely to have conceived in any given monthly cycle,
the study found. Women on rescue medications were also 30 percent
more likely to have taken more than 12 months to conceive.
“While we found that asthma was linked with reduced fertility, the
most striking finding was that this relationship was only observed
among the group of women relying on short-acting asthma relievers
alone to manage their asthma,” said lead study author Dr. Luke
Grzeskowiak of the University of Adelaide.

“No relationship between the use of long-acting preventer asthma
medications and fertility was seen,” Grzeskowiak said by email.
“This provides reassuring evidence that women using long-acting
asthma medications, to prevent asthma symptoms and maintain good
asthma control, should continue to take these when trying to
conceive.”
Long-acting asthma medications such as inhaled corticosteroids work
by reducing inflammation in the lungs. Inflammation is a key step in
triggering narrowing of the airways, which makes it more difficult
for those with asthma to breathe.
While short-acting asthma medications can help relax the airway to
treat asthma symptoms, such as wheezing, they are not able to reduce
the underlying inflammation and therefore cannot prevent future
symptoms.
Several studies have linked asthma to reproduction-related problems
in women, but results have been mixed and the connection is poorly
understood.
The study wasn’t a controlled experiment designed to prove whether
or how asthma or short-acting asthma drugs might directly cause
infertility. It’s possible that some women might struggle to
conceive if their asthma was poorly controlled with short-acting
medications.

[to top of second column] |

Another limitation is that researchers relied on women to accurately
recall and report on any current or prior asthma diagnosis.
Researchers also lacked data on asthma control and lung function
during pregnancy.
But it’s possible that inflammation may play a role in making it
harder to conceive, and the findings suggest that women with asthma
should take steps to manage symptoms before trying to conceive,
researchers note in the European Respiratory Journal.
“It has been hypothesized that asthma reduces uterine blood supply
and increases infiltration of inflammatory cells into the (uterine
lining), which impairs implantation and fertility,” said Dr. Eyal
Sheiner of Soroka University Medical Center and Ben-Gurion
University of the Negev in Beer-Sheva, Israel.
“Preventer medications may play a protective role in improving
asthma control and reducing associated systemic inflammation which
may drive impaired fertility,” Sheiner, who wasn’t involved in the
study, said by email.
Poorly controlled asthma during pregnancy can increase the risk that
women will develop a severe form of high blood pressure known as
preeclampsia, and it can also lead to restricted fetal growth and
preterm deliveries as well as underweight infants.

Like many medications, long-acting preventive asthma drugs and
inhaled corticosteroids haven’t been tested in pregnant women or
proven safe for use during pregnancy. Doctors often advise women
with asthma to get regular lung function tests during pregnancy, and
to take medications if they have severe symptoms.
“Safety concerns may lead to poor adherence and discontinuation of
asthma medications during pregnancy, with negative impacts on asthma
control and pregnancy outcomes,” Sheiner said. “It is important to
know that these medications improve pregnancy outcomes, and also
fertility.”
SOURCE: http://bit.ly/2oObEAi European Respiratory Journal, online
February 14, 2018.
[© 2018 Thomson Reuters. All rights
reserved.] Copyright 2018 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content. |